AGM/EGMJul 2, 2026, 05:27 PM
Akari Therapeutics Shareholders Reject James Neal's Re-election to Board
AI Summary
Akari Therapeutics Plc held its Annual General Meeting on June 30, 2026, where shareholders voted on several key proposals. While most resolutions passed, including the approval of financial reports, auditor appointments, and various share issuance authorizations, the re-election of James Neal as a Class A Director was rejected. Other directors, including Hoyoung Huh, Robert Bazemore, Sandip I. Patel, Samir R. Patel, and Abizer Gaslightwala, were successfully re-elected.
Key Highlights
- James Neal's re-election as a Class A Director was rejected with 29.03 billion votes against.
- Hoyoung Huh, Robert Bazemore, Sandip I. Patel, Samir R. Patel, and Abizer Gaslightwala were re-elected as directors.
- Shareholders approved the Board of Directors' report and accounts for the year ended December 31, 2025.
- The advisory and policy for the Board of Directors' Remuneration Report were approved.
- BDO USA, P.C. was ratified as the independent registered public accounting firm for 2026.
- HaysMac LLP was re-appointed as statutory auditors.
- Approval was granted for the issuance of ordinary shares under the ELOC Purchase Agreement.
- Approval was given for the potential issuance of shares in a private placement that could result in a change of control.
Price Impact
More from AKTX